R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
R&D Partner Content Register Now for the AAPS National Biotechnology Conference The AAPS National Biotechnology Conference uncovers the trends driving today’s biotech markets.
Market Access Why the NHS needs to maximise the impact of biosimilars Ensuring the long-term sustainability of the NHS increasingly appears to be an unfathomable prospect.
News AMD shadows NVIDIA with a move into AI drug discovery Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
News Sanofi opens $595m manufacturing facility in Singapore Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products
News Push for self-injected drugs prompts Novartis/Lindy alliance Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be s
News Controversial project aims to make artificial human genomes A landmark project funded by Wellcome aims to develop the tools needed to synthesise human genomes – and simultaneously probe the social implications.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face